Clinical Trials
57 trialsTRIDENT-1
Turning Point Therapeutics, Inc.
EVEREST-2
A2 Biotherapeutics Inc.
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Revolution Medicines, Inc.
The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia.
New Phase Ltd.
Adaptive Symptom Self-Management Immunotherapy Study
University of Arizona
Brodalumab in the Treatment of Immune-Related Adverse Events
Columbia University
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
ALX Oncology Inc.
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Kestrel Therapeutics, Inc.
A Multilevel Approach to Connecting Underrepresented Populations to Clinical Trials
University of Florida
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ModeX Therapeutics, An OPKO Health Company
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Alterome Therapeutics, Inc.
iCaRe2
University of Nebraska
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Orano Med LLC
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Stanford University
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Revolution Medicines, Inc.
Collection of Blood From Patients With Cancer
National Institutes of Health Clinical Center (CC)
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
Pfizer
A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1)
Aurigene Discovery Technologies Limited
A Study of PHN-012 in Patients With Advanced Solid Tumors
Pheon Therapeutics
PSI-Immune
University of Pittsburgh
Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies
National Institutes of Health Clinical Center (CC)
ASAP
Avera McKennan Hospital & University Health Center
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
RasCal Therapeutics, Inc.
PRO-ACTIVE
Fondazione del Piemonte per l'Oncologia
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Xencor, Inc.
Phase II Trial of Lung Chemoemobolization
City of Hope Medical Center
miR-CIPN#1
University Hospital, Clermont-Ferrand
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
Washington University School of Medicine
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
Arvinas Inc.
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
MBrace Therapeutics
Evaluation of the Effectiveness of Managing Chemotherapy Side Effects Using ePRO and a Standardized Telenursing Program for Cancer Patients
Ulsan University Hospital
Improving Care for Rural Patients With Solid Tumors
University of Colorado, Denver
ID-COMET
Roswell Park Cancer Institute
EXoPERT EMERALD Clinical Study
EXoPERT
VARTUTRACE
Var2 Pharmaceuticals
LIBERATE
University Health Network, Toronto
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Massive Bio, Inc.
EXCEL
University of Calgary
CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors
Chongqing Precision Biotech Co., Ltd
RESET
Stony Brook University
DENALI-1
A2 Biotherapeutics Inc.
RCT-SE
Centre Hospitalier de Valence
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Revolution Medicines, Inc.
A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors
GONGCHU Biotechnology Co., Ltd
SPARTA
Apollomics Inc.
UMBRELLA
Gustave Roussy, Cancer Campus, Grand Paris
ALCINA2
Institut du Cancer de Montpellier - Val d'Aurelle
Personalized DC Vaccine for Postoperative Cancer
Sichuan University
Development and Demonstration of Intelligent Assessment Based on Multi-modal Information Fusion for Tumor Risk and Diagnosis and Treatment
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology